WuXi Biologics (Cayman) Inc.
2269
주식 순위
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
주가
$5.77
시가총액
$23.74B
변동 (1일)
-8.38%
변동 (1년)
25.13%
국가
CN
거래 WuXi Biologics (Cayman) Inc. (2269)
카테고리
Healthcare
WuXi Biologics (Cayman) Inc. (2269)의 매출
Oct 2026 기준 매출 TTM: 0
WuXi Biologics (Cayman) Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
WuXi Biologics (Cayman) Inc.의 수익 기록 (2014 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2025 | $3.11B | 21.73% |
| 2024 | $2.56B | 6.32% |
| 2023 | $2.41B | 8.72% |
| 2022 | $2.21B | 36.72% |
| 2021 | $1.62B | 88.45% |
| 2020 | $859.12M | 50.17% |
| 2019 | $572.10M | 55.27% |
| 2018 | $368.45M | 48.08% |
| 2017 | $248.81M | 74.67% |
| 2016 | $142.45M | 66.06% |
| 2015 | $85.78M | 60.11% |
| 2014 | $53.58M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
